Morgan Stanley sees ‘nothing thesis changing’ in Grail results

Morgan Stanley says Grail’s (GRAL) preliminary Q4 results contain “nothing thesis changing.” The firm keeps an Equal Weight rating on the shares with a $110 price target Grail’s execution remains on track with a “modest” Q4 revenue beat and 2026 guidance that exceeds consensus estimates, the analyst tells investors in a research note. Morgan Stanley sees the stock trading around current levels as investors await the NHS-Galleri readout. Grail in afternoon trading is up 3% to $103.08.